Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 9
2017 6
2018 7
2019 9
2020 6
2021 7
2022 5
2023 8
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease.
Schuppan D, Mäki M, Lundin KEA, Isola J, Friesing-Sosnik T, Taavela J, Popp A, Koskenpato J, Langhorst J, Hovde Ø, Lähdeaho ML, Fusco S, Schumann M, Török HP, Kupcinskas J, Zopf Y, Lohse AW, Scheinin M, Kull K, Biedermann L, Byrnes V, Stallmach A, Jahnsen J, Zeitz J, Mohrbacher R, Greinwald R; CEC-3 Trial Group. Schuppan D, et al. N Engl J Med. 2021 Jul 1;385(1):35-45. doi: 10.1056/NEJMoa2032441. N Engl J Med. 2021. PMID: 34192430 Free article. Clinical Trial.
NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22.
Spalinger MR, Kasper S, Gottier C, Lang S, Atrott K, Vavricka SR, Scharl S, Gutte PM, Grütter MG, Beer HD, Contassot E, Chan AC, Dai X, Rawlings DJ, Mair F, Becher B, Falk W, Fried M, Rogler G, Scharl M. Spalinger MR, et al. Among authors: scharl s. J Clin Invest. 2023 Feb 15;133(4):e169304. doi: 10.1172/JCI169304. J Clin Invest. 2023. PMID: 36787260 Free PMC article. No abstract available.
[Treatment of primary oligometastatic prostate cancer].
Scharl S, Hadaschik B, Wiegel T, Thomas C. Scharl S, et al. Urologe A. 2021 Dec;60(12):1527-1533. doi: 10.1007/s00120-021-01643-0. Epub 2021 Nov 26. Urologe A. 2021. PMID: 34825936 Review. German.
The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy.
Adebahr S, Althaus A, Scharl S, Strouthos I, Farolfi A, Serani F, Lanzafame H, Trapp C, Koerber SA, Peeken JC, Vogel MME, Vrachimis A, Spohn SKB, Grosu AL, Kroeze SGC, Guckenberger M, Fanti S, Hruby G, Emmett L, Belka C, Schmidt-Hegemann NS, Henkenberens C, Aebersold DM, Wiegel T, Afshar-Oromieh A, Zamboglou C, Shelan M. Adebahr S, et al. Among authors: scharl s. Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):558-567. doi: 10.1007/s00259-023-06438-3. Epub 2023 Sep 22. Eur J Nucl Med Mol Imaging. 2024. PMID: 37736808 Free PMC article.
Crosstalk within peripheral blood mononuclear cells mediates anti-inflammatory effects of n-3 PUFA-rich lipid emulsions in parenteral nutrition.
Wawrzyniak P, Hubeli B, Wawrzyniak M, Noureddine N, Walberg A, Scharl S, Turina M, Scharl M, Zaugg M, Krämer SD, Rogler G, Hersberger M. Wawrzyniak P, et al. Among authors: scharl s. Clin Nutr. 2023 Dec;42(12):2422-2433. doi: 10.1016/j.clnu.2023.10.016. Epub 2023 Oct 17. Clin Nutr. 2023. PMID: 37871483 Free article.
Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer.
Zamboglou C, Peeken JC, Janbain A, Katsahian S, Strouthos I, Ferentinos K, Farolfi A, Koerber SA, Debus J, Vogel ME, Combs SE, Vrachimis A, Morganti AG, Spohn SKB, Shelan M, Aebersold DM, Grosu AL, Ceci F, Henkenberens C, Kroeze SGC, Guckenberger M, Fanti S, Belka C, Bartenstein P, Hruby G, Scharl S, Wiegel T, Emmett L, Arnoux A, Schmidt-Hegemann NS. Zamboglou C, et al. Among authors: scharl s. JAMA Netw Open. 2023 May 1;6(5):e2314748. doi: 10.1001/jamanetworkopen.2023.14748. JAMA Netw Open. 2023. PMID: 37219907 Free PMC article.
Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis.
Trapp C, Aebersold DM, Belka C, Casuscelli J, Emmett L, Eze C, Fanti S, Farolfi A, Fendler W, Grosu AL, Guckenberger M, Hruby G, Kirste S, Koerber SA, Kroeze S, Peeken JC, Rogowski P, Scharl S, Shelan M, Spohn SKB, Strouthos I, Unterrainer L, Vogel M, Wiegel T, Zamboglou C, Schmidt-Hegemann NS. Trapp C, et al. Among authors: scharl s. Eur J Nucl Med Mol Imaging. 2024 Oct;51(12):3770-3781. doi: 10.1007/s00259-024-06802-x. Epub 2024 Jun 28. Eur J Nucl Med Mol Imaging. 2024. PMID: 38940843 Free PMC article.
European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy.
Scharl S, Zamboglou C, Strouthos I, Farolfi A, Serani F, Koerber SA, Debus J, Peeken JC, Vogel MME, Kroeze SGC, Guckenberger M, Krafcsik M, Hruby G, Emmett L, Schmidt-Hegemann NS, Trapp C, Spohn SKB, Henkenberens C, Mayer B, Shelan M, Aebersold DM, Thamm R, Wiegel T. Scharl S, et al. Radiother Oncol. 2024 May;194:110215. doi: 10.1016/j.radonc.2024.110215. Epub 2024 Mar 7. Radiother Oncol. 2024. PMID: 38458259 Free article.
54 results